Core Viewpoint - Amgen Inc. is set to announce its fiscal fourth-quarter earnings for 2025, with analysts projecting a decline in profit per share compared to the previous year, despite a generally positive outlook for the company's performance and stock growth [1][2]. Financial Performance - Analysts expect Amgen to report a profit of $4.74 per share on a diluted basis for the upcoming quarter, which represents a 10.7% decrease from $5.31 per share in the same quarter last year [2]. - For the full fiscal year, analysts project an EPS of $21.28, reflecting a 7.3% increase from $19.84 in fiscal 2024, with further growth anticipated to $21.69 in fiscal 2026 [3]. Stock Performance - Amgen's stock has outperformed the S&P 500 Index, gaining 22.8% over the past 52 weeks, compared to the S&P 500's 16.2% increase and the Health Care Select Sector SPDR Fund's 11.6% returns [4]. - Following the Q3 results announcement on November 4, 2025, Amgen's shares rose by 7.8% in the subsequent trading session [6]. Growth Drivers - The company's growth is attributed to increasing demand for newer medicines such as Repatha, Tezspire, and Evenity, alongside a diversified product portfolio and successful product launches [5]. - Management anticipates continued growth momentum supported by late-stage pipeline programs and investments in manufacturing and AI technologies, including the AmgenNow platform aimed at improving patient access [5]. Analyst Sentiment - The consensus opinion among analysts is moderately bullish, with a "Moderate Buy" rating overall. Out of 32 analysts, 14 recommend a "Strong Buy," 2 suggest a "Moderate Buy," 13 advise a "Hold," 1 recommends a "Moderate Sell," and 2 advocate a "Strong Sell" [7]. - The average analyst price target for Amgen is $330.74, indicating a potential upside of 3.1% from current levels [7].